GLOBUS MEDICAL INC

GMED

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Driehaus Capital

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 167,762Value: $14.6M

Driehaus Capital's $14.6M initiation in GMED signals conviction in the orthopedic med-tech space, likely driven by the company's expanding robotic surgery platform (ExcelsiusGPS) and international market penetration rather than a near-term binary catalyst. This aligns with growth-stage VC thesis favoring companies with recurring revenue models and secular tailwinds in minimally invasive spine/orthopedic procedures, though watch for upcoming surgeon adoption metrics and international reimbursement decisions as key near-term drivers.

More GMED Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

PTN1 fund WLDN1 fund LASR1 fund ONTO1 fund VALE1 fund TNDM1 fund TKO1 fund TNL1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: